Tarsus Pharmaceuticals Posts 150% Revenue Growth on Xdemvy Success

Key Facts

1FY 2025 revenue surged 150% to $451M.

22026 revenue guidance is set at $670–$700M with 93% gross margins.

3Profitability is now expected in 2027, with US market penetration currently at just 5.6%.

Tarsus Pharmaceuticals reported a significant surge in its fiscal year 2025 performance, with revenues jumping 150% to reach $451 million. The growth is primarily attributed to the commercial success of its flagship drug, Xdemvy, which currently holds a 5.6% penetration rate in the US market, suggesting substantial room for expansion. Looking ahead, the company issued optimistic guidance for 2026, projecting revenues between $670 million and $700 million alongside impressive gross margins of 93%. While the path to profitability has been shifted to 2027, the firm is aggressively pursuing international expansion with planned launches in China and Europe. Analysts remain focused on the drug's blockbuster potential and the company's robust revenue trajectory within the biotech sector.